Search

Your search keyword '"Liesbeth Ferdinande"' showing total 2 results
Start Over Author "Liesbeth Ferdinande" Publisher frontiers media s.a.
2 results on '"Liesbeth Ferdinande"'

1. Clinical Relevance of Serum Kyn/Trp Ratio and Basal and IFNγ-Upregulated IDO1 Expression in Peripheral Monocytes in Early Stage Melanoma

Author

Annabel Meireson, Liesbeth Ferdinande, Marc Haspeslagh, Benjamin Hennart, Delphine Allorge, Piet Ost, Nora Sundahl, Mathieu Spaas, Annelies Demeyer, and Lieve Brochez

Subjects
early stage melanoma, biomarker, IDO1, Kyn/Trp, tryptophan metabolism, monocytes, Immunologic diseases. Allergy, RC581-607
Abstract

Immune escape is an early phenomenon in cancer development/progression. Indoleamine 2,3-dioxygenase 1 (IDO1) is a normal endogenous mechanism of acquired peripheral immune tolerance and may therefore be tumor-promoting. This study investigated the clinical relevance of IDO1 expression by immune cells in the lymph nodes and blood and of the serum kynurenine/tryptophan (Kyn/Trp) ratio in 65 systemic treatment naïve stage I-III melanoma patients. Blood samples were collected within the first year of diagnosis. Patients had a median follow-up of 61 months. High basal IDO1 expression in peripheral monocytes and low IFNγ-induced IDO1 upregulation correlated with worse outcome independent from disease stage. Interestingly studied factors were not interrelated. During follow-up, the risk of relapse was 9% (2/22) in the subgroup with high IFNγ-induced IDO1 upregulation in monocytes. In contrast, if IDO1 upregulation was low, relapse occurred in 30% (3/10) of patients with low basal IDO1 expression in monocytes and in 61.5% (8/13) in the subgroup with high basal IDO1 expression in monocytes (Log-Rank test, p=0.008). This study reveals some immune features in the blood of early stage melanoma that may be of relevance for disease outcome. These may offer a target for sub-stratification and early intervention.

Published
2021
Full Text
View/download PDF

2. EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression

Author

Veerle Surmont, Yolande Lievens, Liesbeth Ferdinande, Katrien Vandecasteele, and Katrijn Van Assche

Subjects
Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Afatinib, Population, Bioinformatics, lcsh:RC254-282, ADVANCED NON-SMALL-CELL LUNG CANCER, Gefitinib, tyrosine kinase inhibitor, Internal medicine, advanced non-small-cell lung cancer, medicine, Medicine and Health Sciences, Epidermal growth factor receptor, education, Lung cancer, EGFR MUTATION, radiotherapy, education.field_of_study, biology, business.industry, Cancer, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Clinical Case Study, respiratory tract diseases, Radiation therapy, local progression, biology.protein, Erlotinib, EGFR mutation, business, TYROSINE KINASE INHIBITOR, medicine.drug, RADIOTHERAPY
Abstract

Non-small-cell lung cancer (NSCLC) is the leading cause of death from cancer for both men and women. Chemotherapy is the mainstay of treatment in advanced disease, but is only marginally effective. In about 30% of patients with advanced NSCLC in East Asia and in 10–15% in Western countries, epidermal growth factor receptor (EGFR) mutations are found. In this population, first-line treatment with the tyrosine kinase inhibitors (TKIs) erlotinib, gefitinib, or afatinib is recommended. The treatment beyond progression is less well-defined. In this paper, we present three patients, EGFR mutation positive, with local progression after an initial treatment with TKI. These patients were treated with local radiotherapy. TKI was temporarily stopped and restarted after radiotherapy. We give an overview of the literature and discuss the different treatment options in case of progression after TKI: TKI continuation with or without chemotherapy, TKI continuation with local therapy, alternative dosing or switch to next-generation TKI or combination therapy. There are different options for treatment beyond progression in EGFR mutation positive metastatic NSCLC, but the optimal strategy is still to be defined. Further research on this topic is ongoing.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results